111 related articles for article (PubMed ID: 34384724)
1. Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center.
Rojas-Pintor KP; Arizmendi-Villarreal MA; Aparicio-Salas JE; Moreno-Peña DP; Hernández-Barajas D; Cordero-Pérez P; Muñoz-Espinosa LE
Rev Gastroenterol Mex (Engl Ed); 2021; 86(4):370-377. PubMed ID: 34384724
[TBL] [Abstract][Full Text] [Related]
2. Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center.
Rojas-Pintor KP; Arizmendi-Villarreal MA; Aparicio-Salas JE; Moreno-Peña DP; Hernández-Barajas D; Cordero-Pérez P; Muñoz-Espinosa LE
Rev Gastroenterol Mex (Engl Ed); 2021 Mar; ():. PubMed ID: 33676785
[TBL] [Abstract][Full Text] [Related]
3. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
4. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery.
Lee SD; Park SJ; Han SS; Kim SH; Kim YK; Lee SA; Ko YH; Hong EK
Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):594-601. PubMed ID: 25475861
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
[TBL] [Abstract][Full Text] [Related]
7. Histological differentiation predicts post-liver transplantation survival time.
Li WX; Li Z; Gao PJ; Gao J; Zhu JY
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
[TBL] [Abstract][Full Text] [Related]
8. Liver transplantation in patients with incidental hepatocellular carcinoma/cholangiocarcinoma and intrahepatic cholangiocarcinoma: a single-center experience.
Elshamy M; Presser N; Hammad AY; Firl DJ; Coppa C; Fung J; Aucejo FN
Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):264-270. PubMed ID: 28603094
[TBL] [Abstract][Full Text] [Related]
9. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation.
Lunsford KE; Court C; Seok Lee Y; Lu DS; Naini BV; Harlander-Locke MP; Busuttil RW; Agopian VG
Liver Transpl; 2018 Oct; 24(10):1384-1397. PubMed ID: 29573187
[TBL] [Abstract][Full Text] [Related]
10. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
11. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
[TBL] [Abstract][Full Text] [Related]
12. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation.
Al-Ameri AAM; Wei X; Lin L; Shao Z; Guo H; Xie H; Zhou L; Zheng S; Xu X
BMC Cancer; 2019 Nov; 19(1):1136. PubMed ID: 31752756
[TBL] [Abstract][Full Text] [Related]
13. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
[TBL] [Abstract][Full Text] [Related]
14. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection.
Jung DH; Hwang S; Song GW; Ahn CS; Moon DB; Kim KH; Ha TY; Park GC; Hong SM; Kim WJ; Kang WH; Kim SH; Yu ES; Lee SG
Liver Transpl; 2017 Mar; 23(3):330-341. PubMed ID: 28027599
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.
Varona MA; Soriano A; Aguirre-Jaime A; Garrido S; Oton E; Diaz D; Portero J; Bravo P; Barrera MA; Perera A
Transplant Proc; 2015; 47(1):84-9. PubMed ID: 25645778
[TBL] [Abstract][Full Text] [Related]
16. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
[TBL] [Abstract][Full Text] [Related]
17. AFP ratio predicts HCC recurrence after liver transplantation.
Koch C; Bette T; Waidmann O; Filmann N; Schrecker C; Trojan J; Weiler N; Vermehren J; Schnitzbauer AA; Bechstein WO; Zeuzem S; Herrmann E; Welker MW
PLoS One; 2020; 15(7):e0235576. PubMed ID: 32614912
[TBL] [Abstract][Full Text] [Related]
18. Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma.
Antwi SO; Habboush YY; Chase LA; Lee DD; Patel T
Ann Hepatol; 2018 Oct; 17(6):969-979. PubMed ID: 30600299
[TBL] [Abstract][Full Text] [Related]
19. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.
Refaat R; Basha MAA; Hassan MS; Hussein RS; El Sammak AA; El Sammak DAEA; Radwan MHS; Awad NM; Saad El-Din SA; Elkholy E; Ibrahim DRD; Saleh SA; Montasser IF; Said H
Eur Radiol; 2018 Dec; 28(12):5356-5367. PubMed ID: 29948070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
